HEPATOLOGY FORUM, vol.3, no.3, pp.82-87, 2022 (ESCI)
Article / Article
Emerging Sources Citation Index (ESCI)
Chronic Hepatitis C infection, direct-acting antiviral agents, hepatocellular carcinoma, VIROLOGICAL RESPONSE, ADVANCED FIBROSIS, CIRRHOSIS, INTERFERON/RIBAVIRIN, RECURRENCE, OUTCOMES, HCC
Recep Tayyip Erdoğan University Affiliated:
Background and Aim: Several studies have suggested that treatment with direct-acting antivirals (DAAs) in patients with chronic hepatitis C virus (HCV) may be associated with an increased risk of developing hepatocellular carcinoma (HCC). We investigated the incidence and risk factors of HCC in HCV patients who achieved a sustained virologic response (SVR) following DAA therapies.